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four-drug regimen), MDR-TB (second-
line therapy), and latent tuberculosis 
infection (isoniazid preventive 
therapy). For tuberculosis treatment, 
we asked at what level therapy can 
be initiated, and at what level such 
therapy can be continued.
In general, very few countries 
have any tuberculosis diagnostic or 
treatment services available at the 
most decentralised L0 level (figure). 
Most countries have chest radiology 
available only at the L2 (13 of 14, 93%) 
or L3 level (14 of 14, 100%), while 
smear microscopy is available, starting 
at the L1 level (14 of 14, 100%). Drug 
susceptibility testing is mainly available 
at the tertiary or referral (L3) level, with 
the majority of countries having at least 
some capacity at L2 (11 of 14, 79%). 
Latent tuberculosis testing capacity is 
mainly available at L2 (ten of 14, 71%) 
and L3 levels (13 of 14, 93%).
Treatment for drug-sensitive 
disease is available in all countries 
at the L1 level, and ten (71%) of 
14 countries are able to continue 
therapy at the L0 level. By contrast, 
most countries (eight of 14, 57%) 
are only able to initiate MDR-TB 
treatment at L2 and L3 levels. Some 
countries are able to continue MDR-
TB therapy at the L1 level, and very 
few can continue MDR-TB therapy 
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Early diagnosis of tuberculosis 
and rapid treatment initiation are 
crucial for tuberculosis care and for 
interrupting transmission1 and require 
delivery of tuberculosis care services 
where most patients seek initial care. In 
most countries, National Tuberculosis 
Programs (NTPs) are expected to have 
basic tuberculosis diagnosis by use 
of smear microscopy available at the 
primary care level, via a network of 
microscopy centres.2 However, there 
is little published information on 
where latent tuberculosis and multi-
drug resistant tuberculosis (MDR-TB) 
diagnostic and treatment services 
are exactly available in the highest 
tuberculosis burden countries. 
We addressed this gap by surveying 
14 countries that have been identiﬁ ed 
by WHO as having the highest burden 
of tuberculosis cases, MDR-TB, and 
co-infection of HIV and tuberculosis.3 
These countries are Angola, China, 
DR Congo, Ethiopia, India, Indonesia, 
Kenya, Mozambique, Myanmar, 
Nigeria, Papua New Guinea, South 
Africa, Thailand, and Zimbabwe.3
We contacted tuberculosis experts in 
these 14 countries between June and 
August, 2016, and asked them about 
diagnosis and treatment availability in 
their countries at each level of health 
care (from the most decentralised to 
the tertiary level). Health-care levels 
were defined as L0, which included 
care by community or village health 
workers or at local health posts; L1, 
which included microscopy centres 
or primary health centres; L2, district 
hospitals or community health centres; 
and L3, reference or tertiary hospitals. 
For ten (71%) of 14 countries, at least 
two completed surveys were obtained. 
Among the respondents were NTP 
and National Reference Laboratory 
staff, tuberculosis researchers, and 
members of international agencies 
(eg, WHO, Foundation for Innovative 
New Diagnostics).
Regarding diagnosis, we asked about 
availability of screening or triage tests 
(eg, chest radiographs), tests for active 
tuberculosis (eg, smear microscopy), 
tests for latent tuberculosis infection 
(eg, tuberculin skin test, interferon-
gamma release assays), and drug-
susceptibility testing (eg, cultures, 
Xpert MTB/RIF, and line probe assays). 
Concerning drug therapy, we asked 
about availability of treatment for 
drug-sensitive tuberculosis (standard 
Figure 1:  Availability of tuberculosis diagnostic and treatment services across various health-care levels in 14 highest burden countries
CXR=chest radiography. LTBI=latent tuberculosis infection. DS=drug sensitive. DST=drug sensitivity testing. MDR-TB=multidrug-resistant TB. L0=care by community 
or village health workers or at health posts. L1=microscopy centres or primary health centres. L2=district hospitals or community health centres. L3=reference or 
tertiary hospitals. TB=tuberculosis.
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at the L0 level (five of 14, 36%). 
About half the surveyed countries 
have isoniazid preventative therapy 
available at L1 centres, while three 
countries reported no infrastructure 
for treatment of latent tuberculosis 
infection at any level. As shown in 
the ﬁ gure, diagnostics and treatment 
availability were not strongly related 
to country income level or geographic 
region. However, our analysis is limited 
because it focused on availability of 
services, rather than access or quality.
The End TB Strategy calls for early 
diagnosis of tuberculosis including 
universal drug susceptibility testing, and 
systematic screening of contacts and 
high-risk groups.1 Mathematical models 
suggest that broad access to new 
methods early in the patient pathways 
can oﬀ er the best impact in terms of 
reducing tuberculosis incidence.4–6
Our analysis shows that although 
most countries have invested in basic 
tuberculosis diagnosis (ie, smears) and 
drug-sensitive tuberculosis treatment 
services at the L1 level and higher, 
availability of triage testing, testing 
for MDR and latent tuberculosis 
infection, and therapy is quite limited 
at the decentralised L0/L1 levels. 
This limitation means that patients 
or samples are being referred, which 
results in losses. Indeed, analyses of 
cascades of tuberculosis care show 
major gaps in the continuum of care, 
and might explain the persistently 
high incidence of tuberculosis in some 
countries.7,8
Our data also suggest that services 
for tuberculosis care in many countries 
might not be fully integrated into 
general health-care services. As 
countries work towards universal 
health coverage, it is crucial to not only 
strengthen tuberculosis services, but 
also ensure greater integration with 
primary health care. In parallel, we 
need to develop simpler methods (eg, 
non-sputum based biomarker tests) 
and drug regimens (eg, a universal 
drug regimen that does not require 
extensive drug-sensitive testing) that 
can be implemented closer to patients.
